Patel RK. Should patients with venous thrombosis have cancer screening? Thrombus 2009; 13.1: 1

Thrombus

Reference list

Patel RK. Should patients with venous thrombosis have cancer screening? Thrombus 2009; 13.1: 1–4.

1. Ahmed Z, Mohyuddin Z. Deep vein thrombosis as a predictor of cancer. Angiology 1996; 47: 261–265.

2. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet 1998; 351: 1077–1080.

3. Carrier M, Le Gal G, Wells PS et al. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med 2008; 149: 323–333.

4. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107: 117–121.

5. Prandoni P, Lensing AW, Buller HR et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128–1133.

6. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 2000; 342: 1953–1958.

7. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338: 1169–1173.

8. White RH, Chew HK, Zhou H et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005; 165: 1782–1787.

9. Cornuz J, Pearson SD, Creager MA, Cook EF, Goldman L. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med 1996; 125: 785–793.

10. Prins MH, Hettiarachchi RJ, Lensing AW, Hirsh J. Newly diagnosed malignancy in patients with venous thromboembolism. Search or wait and see? Thromb Haemost 1997; 78: 121–125.

11. Aderka D, Brown A, Zelikovski A, Pinkhas J. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer. Cancer 1986; 57: 1846–1849.

12. Goldberg RJ, Seneff M, Gore JM et al. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med 1987; 147: 251–253.

13. Hettiarachchi RJ, Lok J, Prins MH, Buller HR, Prandoni P. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer 1998; 83: 180–185.

14. Monreal M, Casals A, Boix J et al. Occult cancer in patients with acute pulmonary embolism. A prospective study. Chest 1993; 103: 816–819.

15. Monreal M, Fernandez-Llamazares J, Perandreu J et al. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 1997; 78: 1316–1318.

16. Monreal M, Lafoz E, Casals A et al. Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer 1991; 67: 541–545.

17. Nordstrom M, Lindblad B, Anderson H, Bergqvist D, Kjellstrom T. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ 1994; 308: 891–894.

18. Trujillo-Santos J, Prandoni P, Rivron-Guillot K et al. Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. J Thromb Haemost 2008; 6: 251–255.

19. Rance A, Emmerich J, Guedj C, Fissinger JN. Occult cancer in patients with bilateral deep-vein thrombosis. Lancet 1997; 1448–1449.

20. Girolami A, Prandoni P, Zanon E, Bagatella P, Girolami B. Venous thromboses of upper limbs are more frequently associated with occult cancer as compared with those of lower limbs. Blood Coagul Fibrinolysis 1999; 10: 455–457.

21. Schutgens RE, Beckers MM, Haas FJ, Biesma DH. The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica 2005; 90: 214–219.

22. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007; 5: 729–737.

23. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153.

24. Lee AY, Rickles FR, Julian JA et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123–2129.

25. Bastounis E, Karayiannakis J, Makri G, Alexiou D, Papalambros E. The incidence of occult cancer in patients with deep venous thrombosis: a prospective study. J Intern Med 1996; 239: 153–156.

26. Monreal M, Lensing AW, Prins MH et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost 2004; 2: 876–881.

27. Piccioli A, Lensing AW, Prins MH et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2004; 2: 884–889.

28. Barosi G, Marchetti M, Dazzi L, Quaglini S. Testing for occult cancer in patients with idiopathic deep vein thrombosis--a decision analysis. Thromb Haemost 1997; 78: 1319–1326.

29. Di Nisio M, Otten H, Piccioli A et al. Decision analysis for cancer screening in idiopathic venous thromboembolism J Thromb Haemost 2005; 3: 2391–2396.

30. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846–1850.

Published by Hayward Medical Communications